Healthcare company GRAIL Inc revealed on Monday the election of Matthew P. Young as its chief operating officer and chief financial officer with effect from 28 October 2019.
Most recently, Young has served as executive vice president and chief financial officer at Jazz Pharmaceuticals, a biopharmaceutical company.
Previously, Young has worked in investment banking at Barclays Capital Inc, Citigroup Global Markets Inc as well as Lehman Brothers Inc.
Currently, Young is a member of the board of PRA Health Sciences Inc's compensation and audit committee as well as lead independent director and chairman of the audit committee of CytomX Therapeutics Inc, a biopharmaceutical company.
GRAIL is focused on developing pioneering technology to for the early detection and identification of multiple deadly cancer types. The uses the power of next-generation sequencing, population-scale clinical studies and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886